Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCare Pharma's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was $0.06.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $0.05.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for InnoCare Pharma's EPS without NRI or its related term are showing as below:
During the past 9 years, InnoCare Pharma's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 49.00% per year. The lowest was -61.30% per year. And the median was 6.00% per year.
INCPF's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.2 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
InnoCare Pharma's EPS (Diluted) for the
six
months ended in Dec. 2025 was $0.06.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.05.
InnoCare Pharma's EPS (Basic) for the
six
months ended in Dec. 2025 was $0.06.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.05.
InnoCare Pharma (OTCPK:INCPF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
InnoCare Pharma EPS without NRI Related Terms
InnoCare Pharma EPS without NRI Historical Data
* Premium members only.
The historical data trend for InnoCare Pharma's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INCPF vs VRTX, REGN, RVMD: EPS without NRI Comparison
For the Biotechnology subindustry, InnoCare Pharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCare Pharma PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InnoCare Pharma's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where InnoCare Pharma's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCare Pharma (INCPF) has a EPS without NRI of $0.05 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on InnoCare Pharma and its competitors. According to the industry distribution chart, InnoCare Pharma ranks #999999 out of 1162 companies in the Biotechnology industry.
Is InnoCare Pharma's EPS without NRI too high?
InnoCare Pharma's current EPS without NRI is $0.05. The Biotechnology industry median EPS without NRI is 16.20. InnoCare Pharma's value of $0.05 is 99.7% below this industry median. Based on the distribution chart, InnoCare Pharma ranks #999999 out of 1162 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, InnoCare Pharma has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, InnoCare Pharma ranks #999999 out of 1162 companies for EPS without NRI. This places InnoCare Pharma in the lower half of its industry. The industry median EPS without NRI is 16.20. InnoCare Pharma's value of $0.05 is 99.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.20, based on 1,162 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCare Pharma's current EPS without NRI of $0.05 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on InnoCare Pharma and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCare Pharma's current EPS without NRI is $0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
InnoCare Pharma (INCPF) has a current EPS without NRI of $0.05. The stock's GF Value™ is $2.32, compared to a current price of $1.55 — trading 33.2% below its estimated fair value. The current EPS without NRI is $0.05 and 99.7% below the Biotechnology industry median of 16.20. InnoCare Pharma's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For InnoCare Pharma (INCPF), the current EPS without NRI is $0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCare Pharma (INCPF) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued.
The current stock price of $1.55 is trading 33.2% below its estimated GF Value™ of $2.32.
Key valuation signals for INCPF:
EPS without NRI: $0.05
GF Value™: $2.32 vs. price of $1.55 (33.2% below fair value)
Industry Position: 99.7% below the Biotechnology median (#999999 of 1162)
No single metric tells the full story. See the INCPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
83GF Score
Get the complete analysis for INCPF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INCPF has been successfully added to your 
